Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Pacific Biosciences of California Inc. buy UBS Group AG

Pacific Biosciences of California Inc.
Start price
€7.17
17.11.23 / 50%
Target price
€9.20
17.11.24
Performance (%)
-79.08%
End price
€1.50
18.11.24
Summary
This prediction ended on 18.11.24 with a price of €1.50. Massive losses of -79.08% were the result for the BUY prediction by UBS_Group_AG. UBS_Group_AG has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Pacific Biosciences of California Inc. 2.374% 2.374% 7.317%
iShares Core DAX® 2,33 % 1,01 % 10,41 %
iShares Nasdaq 100 1,37 % -3,61 % 27,40 %
iShares Nikkei 225® 2,44 % -7,46 % 49,84 %
iShares S&P 500 1,26 % 0,68 % 23,67 %

Comments by UBS_Group_AG for this prediction

In the thread Pacific Biosciences of California Inc. diskutieren
Prediction Buy
Perf. (%) -79.08%
Target price 9.196
Change
Ends at 17.11.24

Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, down previously from $13.00.
Ratings data for PACB provided by MarketBeat

UBS Group AG 
0
Report Share
17.11.23
In the thread Trading Pacific Biosciences of California Inc.
Prediction Buy
Perf. (%) -79.08%
Target price 9.196
Change
Ends at 17.11.24

Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten

UBS Group AG 
0
Report Share
18.11.24

Stopped prediction by UBS_Group_AG for Pacific Biosciences of California Inc.

buy
Pacific Biosciences of California Inc.

Start price
Target price
Perf. (%)
€5.53
16.02.24
€11.13
16.02.25
-67.79%
17.02.25

UBS Group AG 
16.02.24 50%